Login to Your Account



Other News To Note


Wednesday, June 15, 2011
Pacira Pharmaceuticals Inc., of Parsippany, N.J., reported that the FDA extended the PDUFA date for its review of the new drug application for Exparel (bupivacaine extended-release liposome injection), for postoperative analgesia by infiltration, by three months to Oct. 28. The company said it submitted additional information requested by the FDA, which determined that the information constituted a major amendment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription